Josh Fink is the Founder and Managing Member of Luma.
 
Josh is a seasoned investor, leader and philanthropist who has been investing in and supporting multiple companies at the intersection of healthcare and technology.
 
At Luma Group, Josh is deeply involved in all facets of the business, leading the firm’s vision to drive scientific breakthroughs through investments at the intersection of healthcare, biotechnology and advanced computational technologies. He directs the firm’s flagship fund, LumaBio I, deploying capital into early- and mid-stage companies that are harnessing AI, machine learning and data-driven tools to accelerate discoveries in the life sciences. Josh brings over two decades of investment experience to Luma Group, applying his expertise to source proprietary opportunities, evaluate deals and help portfolio companies scale.
 
Beyond investment strategy, Josh plays a hands-on leadership role in fundraising, chairs the investment committee and helps shape the strategic direction of the portfolio. He is instrumental in forging partnerships across pharma, research institutions and the broader healthcare innovation ecosystem, leveraging his extensive network of entrepreneurs, operators and institutional leaders to build lasting value across Luma Group’s platform.
 
Prior to founding Luma Group, Josh was the Founder and Managing Partner of Ophir Holdings, a private investment firm focused on high-growth opportunities across technology, healthcare and natural resources. He is also a founding investor and senior advisor to Altos Labs and National Resilience and was an early investor and advisor to Digital Surgery, acquired by Medtronic. He also co-led Luma Bio-IT SPV, targeting next-generation biotech and medtech ventures.
 
A committed philanthropist, Josh supports global initiatives in healthcare access, education, conservation and the arts. He is actively engaged with the World Economic Forum and serves on the Fund for the Twenty-First Century and the Committee of Drawings and Prints at the Museum of Modern Art, as well as the Chairman’s Council at the Whitney Museum.
 
Josh earned his BA from the University of Pennsylvania in 2000.

LinkedIn

Dr. Themasap Khan, PhD, is a co-founder and Partner of Luma Group.

Themasap was previously VP at Civilization Ventures, a life sciences and health-tech venture firm. He joined the fund shortly after its inception and helped grow the firm into an early-stage biotech powerhouse, backing companies from Series Seed to IPO. Civilization was often the first-money and the lead investor in early-stage biotech companies. Themasap was involved in helping run the firm’s functions across scientific strategy, operations, and business development, and he co-ran the firm’s pioneering Fellowship program.

Themasap has been an author on multiple scientific publications in Nature, Cell and other scientific journals. His research was focused on cancer biology, neuroscience and genomics – with a combined 10+ years spent in life science research labs.

Themasap received his Ph.D. from Stanford University where he was an NSF Graduate Research Fellow and Stanford Graduate Fellow. Themasap earned his BS in Neuroscience from New York University.

LinkedIn

Dr. Jamie Kasuboski, PhD, is a Partner & Head of Research at Luma Group.

Jamie has spent 15 years in biomedical research and over a decade of expertise in the Biotech and Pharmaceutical sectors. Dr. Kasuboski has been involved in investments across more than 18 companies, ranging from pre-clinical to clinical development stages. These companies have successfully raised additional capital and established several industry partnerships. Previously, Jamie served as Vice President at OMX Ventures, RA Capital and Boehringer Ingelheim’s Venture Fund. He has experience on preclinical and clinical-stage therapeutic investments and early-stage research tools.

Jamie’s background in primary research is extensive, spanning over a decade in both pharmaceuticals and academia. Jamie holds a Ph.D. in Cell and Molecular Biology from the University of Notre Dame. Jamie earned his BS in Biology with a Chemistry minor in 2002 from Hillsdale College in Michigan.

LinkedIn

Bill Ryan joined Luma Group in July 2024 as Chief Financial Officer. He previously was Director, Head of Funding Accounting – Private and Public markets at The Rohatyn Group, a global asset manager specializing in emerging markets and real assets. Prior to joining The Rohatyn Group in 2020, Mr. Ryan held positions at Prospect Capital Corporation, Centerbridge Partners L.P. and Fortress Investment Group, LLC.

Mr. Ryan began his career in 2005 in Ernst & Young LLP’s financial services office. Mr. Ryan acts as a strategic advisor on fundraising, fund performance reporting, and all fund operations areas including budget, forecast, liquidity projection, vendor management, accounting and financial reporting, HR and compliance.

Mr. Ryan graduated cum laude with a BS in Accounting from Fairfield University and is a Certified Public Accountant in the state of New York.

LinkedIn

John Gomez is an associate on the investment team at Luma Group and focuses on therapeutics, diagnostic and medical devices. Previously, John worked in life science strategy consulting at ClearView Healthcare Partners where he engaged with leading pharma, biotech and private equity clients. During his time at ClearView he focused on scientific & commercial M&A due diligence, commercial strategy and portfolio strategy for pre-clinical and clinical stage assets.

John graduated with honors from Johns Hopkins University with a degree in Public Health.

LinkedIn

Dr. Miguel (Miggy) Chuapoco, PhD is an Associate at Luma Group on the Investment team.

Prior to Luma Group, Miggy was at Capsida Biotherapeutics, where he was employee #4 and led several pre-clinical studies to drive both internal and partnered programs from proof-of-concept to IND. Previously, Miggy was also a Venture Fellow at Foresite Capital and Scion Life Sciences.

Miggy received his PhD in Bioengineering from Viviana Gradinaru’s lab at Caltech and his BS and MS degrees in Chemical Engineering from Stanford University.

LinkedIn

Dr. Ebright is a Science Fellow at Luma Group and an Oncology Fellow at Dana-Farber Cancer Institute and Mass General Brigham. He earned his medical and graduate degrees from Harvard Medical School and completed his internal medicine residency at Massachusetts General Hospital. In 2020, he was named to the Forbes 30 Under 30 Science list, highlighting his achievements in advancing oncology. His work focuses on innovative cancer treatments, and he is dedicated to improving patient outcomes through cutting-edge research and clinical excellence.

Beyond his medical training, Dr. Ebright is deeply committed to the collaborative nature of oncology, recognizing the critical role of mentorship and teamwork in driving progress. He’s worked at other leading firms as a consultant, including Third Rock and Nextech. His expertise spans both research and clinical practice, with a passion for developing new therapies that can transform the landscape of cancer treatment.

LinkedIn

Dr. Mishra is a Clinical Advisor, guiding Luma Group’s team through investments and diligence processes. Dr. Mishra is passionate about serving underprivileged populations, so he established his clinical base at Montefiore Medical Center, one of the largest healthcare groups in the Bronx, where he also served as Site Director for the Hospital Medicine program and currently assistant professor of Medicine at Albert Einstein College of Medicine. 

Beyond patient care, Dr. Mishra is dedicated to strengthening relationships between hospitals, community organizations and patients. His work extends across both domestic and international settings. In India, he launched a public healthcare initiative to combat the spread of communicable diseases in Uttar Pradesh. His global contributions also include advising on the expansion of emergency medical response systems and serving as a healthcare advisor to international organizations.

LinkedIn

Dr. Negin Mokhtari is a Venture Partner on the investment team at Luma Group and Chief Strategy Officer of Luma’s AI initiative (LABI).  

Negin is a scientist by training with a PhD in Drug and Gene Delivery and brings over a decade of experience building and backing biotech companies. She was previously a Partner at Bioluminescence Ventures, leading investments in companies developing first-in-class and best-in-class therapeutic programs. Before that, she was an investor at Genoa Ventures, backing companies at the intersection of biology and technology and serving on multiple boards. 

In addition to investing, Negin has been a founder and operator, and she has led commercialization and business development at AI-driven biotech companies such as Freenome and several early-stage startups. 

She holds a PhD from the University of California, San Diego and the Moores Cancer Center, where she was a Rita Atkinson Fellow in multidisciplinary research. She earned her BS in Electrical Engineering at the University of Minnesota, Twin Cities and University of Tehran.  

LinkedIn

Dr. Neel Madhukar is Chief Technology Officer at Luma Group’s AI Initiative (LABI).

Neel is a computational biologist and entrepreneur working at the intersection of artificial intelligence, biotechnology, and venture building. At Luma Group, he leads the technical strategy of LABI, a proprietary platform that enhances the firm’s scientific and investment edge in biotech diligence and strategy.

Previously, Neel was the Founder and CEO of OneThree Biotech, an oncology-focused AI drug discovery company. At OneThree, he scaled the platform from inception to multiple clinical-stage programs and secured over $100M in a mix of SAAS and asset-based pharma partnerships. Neel then joined RA Capital as a Senior Director of AI where he helped lead internal incubation efforts to create new companies and products at the forefront of AI-driven healthcare and clinical development.

Neel holds a PhD in Computational Biology and Medicine from Weill Cornell University, where his research focused on using AI to identify novel mechanisms for cancer treatment and progression.

LinkedIn

Dr. James “JJ” Stankowicz leads AI Science and Engineering on LABI.

Prior to Luma Group, JJ worked in venture biotech and on US Department of Defense (DoD) research programs. At RA Ventures, JJ was a Senior Director of AI Science, building AI infrastructure and AI healthcare companies. At Flagship Pioneering, JJ was an original member of the Pioneering Intelligence team, with a focus on using large language models to bootstrap the Flagship innovation pipeline. JJ has led large DoD research programs at both BAE Systems FAST Labs and STR. He has focused on a wide range of topics including multimodal large language models, information extraction, AI forensics, deep learning in signals processing, deep learning on networks, reinforcement learning, and generative AI biology. JJ has several patents and research publications in machine learning and graph theory resulting from this work.

JJ was a Postdoctoral Researcher at the Brown University High Energy Theory group; holds a PhD in Theoretical Physics from UCLA where he was an NDSEG scholar; and holds a BS in Physics from the University of Florida Honors College where he graduated summa cum laude.

LinkedIn

Richie Santry is the Chief of Staff at Luma Group, supporting senior leadership and the investment team across a variety of initiatives. Prior to joining the team, Richie worked at Nomura on the Equity Capital Markets team in the Investment Banking Division.

Richie graduated from Dartmouth College with a double major in Government and Environmental Studies and was a four-year member of the men’s heavyweight rowing team.

LinkedIn

Tamara Young has lived and worked across three continents, bringing a global perspective to her career. She has contributed to renowned global organizations such as Etihad Airways and Carnival Cruise Line. Tamara ensures efficient operations and supports senior leadership in achieving their strategic goals.

Tamara holds a bachelor’s degree in journalism from the University of Novi Sad, Serbia.

LinkedIn

Shaye Ciccarone is the administrative assistant at Luma Group. In her role as administrative assistant Shaye oversees Luma Group’s social media and assists the team with a variety of projects.

Prior to joining Luma Group, Shaye was a Peace Corps Volunteer serving in Rwanda as an English Education Teacher Trainer. She then completed a master’s degree in international relations from Seton Hall University, where she focused on International Development and Global Negotiations, and held an internship with the Gbowee Peace Foundation Africa-USA.

Shaye earned a bachelor’s degree in English from Rutgers University.